Clal Biotechnology Industries and Teva Pharmaceuticals Solidify their Collaboration for Final Stage Development of Diabetes Drug
06-Dec-2007 -
Clal Biotechnology Industries Ltd. announced recently that Andromeda Biotech Ltd., a wholly owned subsidiary of CBI, signed a Term Sheet with Teva to develop and commercialize DiaPep277, an innovative and advanced drug for the treatment of type 1 diabetes. According to the Term Sheet, Teva and ...
TEVA
Teva Pharmaceutical